Executive Team

Sam Raha has served as president and chief executive officer and member of the board of directors at Myriad Genetics since April 2025. He is guided by Myriad’s mission to advance health and well-being for all, by focusing on the needs of patients and the healthcare providers who serve them. He joined Myriad in December 2023 as chief operating officer and played an integral role in shaping Myriad’s long-term growth strategy, while delivering new perspectives and expertise to advance business initiatives, operational excellence, and profitability.

Sam has more than 30 years of proven experience in the life sciences and diagnostics industry. Before joining Myriad, he was the president of Agilent’s Diagnostics and Genomics Group with overall responsibility for the Group’s strategy, innovation, and results. Prior to Agilent, he led marketing and product at Illumina, and before that was the VP and general manager of the TaqMan/qPCR business at Life Technologies.

Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.

Maggie Ancona, senior vice president, Transformation and Chief of Staff to the CEO, joined Myriad Genetics in January 2021. Previously, she led Global Transformation and Program Management at Hewlett Packard (HP) and Dell Technologies where she oversaw business transformation strategy, executed large-scale programs and cost management efforts, while retooling digital infrastructure for the future. Mrs. Ancona received a bachelor’s degree in English from the University of San Francisco.

Patrick Burke was promoted to EVP of Strategy and Innovation in May 2021, responsible for corporate development, Myriad’s companion diagnostics business, digital strategy and partnerships with large health systems and health care providers. In addition to these functions, he leads the executive strategy team and the development long term corporate strategy. Dr. Burke joined Myriad in 2001 and has more than 20 years of experience in the precision medicine and pharmaceutical industries. He received his PhD in Experimental Cell Biology from the University of Utah, School of Medicine and his BA in Molecular Biology from the University of California, San Diego.

Brian Donnelly has served as the Chief Commercial Officer at Myriad Genetics since May 2025, where he oversees global commercial strategy and execution across all business units, including marketing, sales, product management, business development, and customer experience. He brings over 20 years of leadership experience across diagnostics, genomics, and consumer health, with prior roles at Ancestry, Amazon, Illumina, and GlaxoSmithKline. Recognized by Forbes as one of the Top 50 Most Entrepreneurial CMOs in 2025, Mr. Donnelly serves on corporate and advisory boards and holds an MBA and J.D. from Rutgers University.

Jennifer Fox, Chief Legal Officer, joined Myriad Genetics in September 2024. Prior to joining Myriad Genetics, she worked as the Executive Vice President of External Affairs for Emergent BioSolutions where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she held positions with Brinks, Gilson & Lione, Novozymes North America and GSK. She earned a Bachelor of Science in Biology from the University of Toledo, a Master of Science in Biochemistry also from the University of Toledo, and a J.D. from North Carolina Central University.

Kevin R. Haas, chief technology officer, joined Myriad Genetics in May 2013. Previously, he was vice president of Bioinformatics. Dr. Haas also serves on the Board of Directors and is vice president for USA Triathlon, the non-profit national governing body for the sport. Dr. Haas received a B.S. from University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics from single molecule fluoresce. He has co-authored 16 peer reviewed publications and eight patent applications.

Scott Leffler is Myriad’s chief financial officer, focusing on leading the company’s financial team and strategy to advance Myriad’s long-term growth and profitability.

He joined Myriad in January 2024, bringing nearly 20 years of finance experience across a broad range of healthcare and payer market segments at public and private equity-backed companies, with expertise in finance transformation, acquisitions and integrations, and risk management.

Before joining Myriad, he was the CFO of Clover Health. Prior to Clover Health, he was CFO and Treasurer at Sotera Health.

He earned his B.A. in economics and history from Yale University and an M.B.A. from Emory University.

Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.

Shereen Solaiman, chief people officer, joined Myriad Genetics in March 2023. She has more than twenty years of professional experience in the human resources field. Before joining Myriad, she was senior vice president and chief human resources officer at OhioHealth, where she drove business results through talent development at all levels. Shereen received her master’s degree in Public Administration from New York University and her bachelor’s degree in Journalism/Public Relations from Ohio University.

Mark Verratti has served as chief operating officer at Myriad Genetics since April 2025, where he is focused on driving growth through strengthening operations and customer experience. Previously, Mark served as chief commercial officer, responsible for accelerating commercial and marketing capabilities, gaining new customer insights, and enhancing demand generation. He joined Myriad Genetics in 2017 as president of Myriad’s Mental Health business, including the GeneSight^® pharmacogenomics test.

With more than 25 years of experience leading large commercial organizations in the pharmaceutical and medical device industries, Mark has held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from Penn State University.